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ABSTRACT We evaluated the perioperative safety
profile and efficacy of cytoreductive surgery (CRS) plus
hyperthermic intraperitoneal chemotherapy (HIPEC) in 21
patients with peritoneal carcinomatosis (PC) from gastro-
intestinal and gynecological cancers. Twenty-one patients
with PC (12 gastric cancer, 5 colorectal cancer, 2 ovarian
cancer, 1 pseudomyxoma peritonei, 1 malignant mesothe-
lioma) were treated with CRS ? HIPEC with
hydroxycamptothecin 20 mg and mitomycin C 30 mg in
12,000 mL of normal saline at 43 ± .5C for 60 to
90 minutes. Vital signs were recorded for 5 days after
surgery. We analyzed the following: local and systemic
infections; gastrointestinal function recovery; hematologi-
cal, hepatic, and renal parameters; wound healing time;
adverse events; survival; and quality of life. The PC index
was 2 to 33 (median, 11), the duration of operation 4 to
10 h (median, 8 h), and the highest temperature during 5
postoperative days 38.1C. Two patients developed gen-
eralized edema and were successfully treated. Five patients
developed hypoproteinemia on day 1 after surgery. All
routine blood tests checked at 1 week after surgery were
normal. Time of gastric tube removal was 2 to 7 days.
Liquid food intake time was 3 to 8 days. Time of removal
of stitches was 8 to 18 days. No local or systemic infec-
tions, wound disruption, or other clinically important
adverse events occurred. The follow-up was 8 to
43 months (median, 22.5 months). Eleven patients died,
three survived with tumor, and seven survived free of
tumor. CRS ? HIPEC was well tolerated in our selected
patients with PC, some of whom had improved survival.
The locoregional progression of gastrointestinal and
gynecological cancers usually results in peritoneal carci-
nomatosis (PC), which is characterized by the presence of
tumor nodules of various size, number, and distribution on
the peritoneal surface, with a very poor prognosis
of \6 months’ median survival.1–4 The most widely
accepted therapies for such PC are systemic chemotherapy,
best support care, and palliative treatment, without any
hope of cure. Moreover, surgery alone can only remove the
bulky visible tumor burden. For the micrometastases,
invisible free cancer cells, and those tumors not suitable for
resection, surgery cannot achieve any effect. Therefore,
neither surgery nor chemotherapy alone can make an
obvious difference in terms of quantity and quality of life
in patients with PC.
To tackle this problem, a new treatment modality called
cytoreductive surgery (CRS) plus hyperthermic intraperi-
toneal chemotherapy (HIPEC) has been developed as novel
treatment for PC. Here, we summarize the results of a
phase I clinical trail conducted in our center.
PATIENTS AND METHODS
Patients
From January 2005 to January 2007, 21 patients with PC
have been treated with CRS ? HIPEC at the Cancer
Center of Wuhan University, including 5 patients with
colorectal cancer, 12 with gastric cancer, 2 with ovarian
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cancer, 1 with pseudomyxoma peritonei, and 1 with
malignant mesothelioma. Major clinicopathological char-
acteristics of the patients are listed in Table 1.
CRS ? HIPEC
The study protocol was approved by the ethical com-
mittee of Zhongnan Hospital of Wuhan University, and all
the patients provided written informed consent to partici-
pate in the study. The abdominal exploration was
performed under general anesthesia and hemodynamic
monitoring through a midline xiphoid-pubic incision. Once
the abdominal wall was open, a detailed evaluation of the
PC was conducted, taking into consideration the size and
distribution of disease, according to a principle previously
described.5 When the PCI evaluation was finished, maxi-
mal CRS was performed, including the resection of the
primary tumor with acceptable margins, any involved
adjacent structures, lymphadenectomy, and peritoneoto-
mies where peritoneal surfaces were involved by tumor,
according to previously published surgical guidelines.5
After surgery, HIPEC was performed before the closure
of abdominal cavity because this open technique is
believed to provide optimal thermal homogeneity and
spatial diffusion,5,6 with 12 L of heated saline containing
20 mg of hydroxycamptothecin and 30 mg of mitomycin C
(MMC). An outflow tube for perfusion was placed in the
Douglas pouch just before HIPEC. The perfusion solution
was heated to 43.0 ± .5C in a thermostatic water bath and
infused into the peritoneal cavity at a rate of 200 mL/min
through the inflow tube introduced from an automatic
perfusion pump. The skin of the abdomen is attached to a
retract ring, and a plastic sheet covered the open wound to
keep the temperature stable. The perfusion in the peritoneal
cavity was stirred manually with care not to infuse directly
on the bowel surface. The first 1 L of perfusion solution
was discarded through a drainage tube to wash out the
residual debris and detached tumor cells, and the remaining
solution was kept to circulate in the perfusion system. The
temperature of the perfusion solution in the peritoneal
space was monitored with a thermometer in real time. The
total HIPEC procedure time was 60 to 90 min. After HI-
PEC, the perfusion solution in the abdominal cavity was
removed through the suction tube, and drainage tubes were
placed at appropriate sites depending on the type of pri-
mary operation. The wound was closed with a relaxing
suture, and patient was sent to the recovery room.
The extent of CRS was determined by previously pub-
lished criteria on the completeness of cytoreduction
(CCR).7,8 A CCR score of 0 indicates no residual perito-
neal disease after CRS; 1 represents \2.5 mm of residual
disease; 2 indicates residual tumor between 2.5 mm and
2.5 cm; and 3 indicates [2.5 cm of residual tumor or the
presence of a sheet of unresectable tumor nodules.
Postoperative Monitoring and Follow-Up
All patients were closely monitored for the following
parameters: vital signs, bowel sound, flatus passage, drain-
age, and any discharges. The complete peripheral blood tests
and blood chemistry were examined on the second postop-
erative day. Pulmonary cardiovascular functions were
monitored.
Once the bowel function fully recovered, the naso-
gastric tube was removed, and the patient was placed on a
trial liquid diet, which was gradually changed to semi-
liquid and soft food. The wound was examined daily, with
the clinician paying particular attention to any signs of
possible infection. All the information, including the time
to drainage tube removal, time to suture removal, and the
time on liquid food, was recorded on a special form.
When patients could eat soft food and the wound suture
was completely removed, they were discharged. The
chemotherapy that followed was based on routine
procedure.
All patients were routinely followed up by outpatient
clinic or by telephone, and the information was recorded.
The last time of follow-up was on August 1, 2008.









Poorly differentiated adenocarcinoma 4
Intermediately differentiated adenocarcinoma 5








Serous cystic adenocarcinoma 1
Serous papillary cystic adenocarcinoma 1
Pseudomyxoma peritonei 1
Malignant mesothelioma 1
Peritoneal carcinomatosis index (range) 2–33
Completeness of cytoreduction (range) 0–3
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Statistical Analysis
Data were obtained from a database of clinical records,
surgical reports, medical imaging reports, laboratory and
pathology reports, and follow-up records. A serious
adverse event was defined as a recurrence at any site or as a
disease-related death. The survival time was calculated
from the date of first CRS ? HIPEC to the date of patient
death due to any cause. The numerical data were directly
recorded, and the category data were recorded into differ-
ent categories. Data were analyzed by SPSS software,
version 13.0 (SPSS, Chicago, IL), with P \ .05 considered
to be statistically significant.
RESULTS
All patients underwent successful resection. The time of
surgery ranged from approximately 4–10 h (median, 6 h,
mean 6 ± 1.5 h). The volume of blood loss during surgery
was 500 to 3000 mL, blood transfusion was 400 to
2200 mL, and fluid infusion was 2000 to 6500 mL. Eight
patients received resection involving one organ part, 13
patients had resections involving more than one organ part,
and 10 patients underwent partial peritonectomy greater
than one quadrant of the abdomen. All patients received
relaxation sutures. Ten patients transferred to the common
ward after surgery, while 11 patients entered intensive care
unit after surgery.
Successful wound healing was realized in all patients, and
no wound infection or disruption occurred. The time to
suture removal ranged from 8 to 18 days (median, 13 days),
time of flatus passage from 2 to 7 days (median, 4 days),
time of fluid intake from 3 to 8 days (median, 6 days), and
time to drainage tubes removal from 3 to 9 days (median,
6 days). No major postoperative complications occurred,
although two patients developed grade I generalized edema
with puffiness of the face, arms, and legs and were treated
with plasma and albumin transfusion and diuretics. The
edema was relieved after 2 days.
Vital Signs
The numbers of patients with body temperature over
37C were 13, 10, 3, and 1 on days 1, 2, 3, and 4 after
surgery (Table 2). No patient experienced absorptive fever
after the major operation. The hemodynamics parameters
were stable, and no arrhythmia occurred.
Laboratory Results
Among the 21 patients, 3 had aspartate aminotransferase
of [46 U/L after surgery. Seven days postoperatively, only
1 patient had aspartate aminotransferase of [46 U/L. Five
patients developed hypoproteinemia, but other laboratory
results were normal (Table 3).
Adverse Events
No clinically important adverse events occurred in the
perioperative period except for some minor abnormal lab-
oratory results, and two patients (9.5%) experienced edema
of the face and upper extremities.
Survival
The last follow-up was on August 1, 2008, by either
outpatient clinic or by telephone. The follow-up time ran-
ged from 8 to 43 months (median, 22.5 months) for all PC
patients, 29 months (range, 8–43 months) for PC patients
of gastric origin, and 18 months (range, 8.5–26.5 months)
for PC of colorectal origin. Eleven patients died of disease
progression, one due to rectal carcinoma recurrence to
ovary with 8.5-month survival, one due to rectal cancer
widespread metastases to abdominal cavity with 18-month
survival, one due to colon cancer widespread metastases to
abdominal cavity with 15.5-month survival, one due to
ovarian cancer metastases to the whole abdominal cavity
with 9-month survival, one due to malignant mesothelioma
metastases to the whole abdominal cavity with 30.5-month
survival, and the other six deaths due to gastric cancer
progression with survivals of 8, 9.5, 10.5, 12, 15, and
29.5 months, respectively. Three patients survived with
disease, while another seven patients experienced disease-
free survival with satisfactory performance status.
The overall survival curve of 21 patients and those PC
patients from gastric, colorectal, and ovarian origins are
presented in Fig. 1, and detailed information for each
patient is summarized in Table 4.
DISCUSSION
Neither surgery nor chemotherapy or radiotherapy alone
can make any important differences in terms of quantity
and quality of life in patients with PC. To tackle this dif-
ficult problem, in the 1990s, a new treatment modality
called CRS ? HIPEC was developed, which has the
advantages of surgery to reduce the visible tumor burden
and regional hyperthermic chemotherapy to eradicate mi-
crometastases and free cancer cells.9 Since then, over 20
phase I and II studies have been conducted with promising
results, and this new treatment modality has gained
increasingly wide acceptance in the treatment of PC from
colorectal origin at cancer centers in North America,
France, Italy, German, Holland, Spain, Australia, Japan,
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and South Korea.10–13 After the randomized clinical trial
by Netherland Cancer Center, a suggestion has been made
to consider CRS and HIPEC the standard of care for
patients with isolated colorectal PC.11,14–17
This phase I clinical study was performed after an ani-
mal study, which showed important benefit of
intraperitoneal chemotherapy for PC.18 For the 21 patients
enrolled onto this study, the perioperative safety profile
was satisfactory. There were no postoperative infections
and no wound disruption because we used relaxation
sutures during surgery and we delayed the time of removal
of stitches. The heart rates of all patients were within
normal limits during the 5 days after surgery, and all
patients were hemodynamically stable. The highest tem-
perature recorded was 38.1C, and there was no absorp-
tion fever, which usually occurs after major abdominal
surgery; the reason may be irrigation and clearance of
abdominal cavity from blood residue during the HIPEC
process. On the other hand, the heated chemotherapeutic
agents can restrain the activity of inflammatory cells in the
abdominal cavity and consequently reduce the release of
cytokines, which leads to postoperative fever. Although
there is no current evidence to support these hypotheses,
they can be further tested in future trials. The gastrointes-
tinal function recovery was optimal in these patients. Only
two patients developed generalized edema, which might be
TABLE 2 Important monitoring data during the 5 days after surgery
Index Range (median)
Day 1 Day 2 Day 3 Day 4 Day 5
Temperature (C) 36.7–38.1 (37.3) 36.7–38.0 (37.3) 36.2–37.2 (36.8) 36.3–37.2 (36.8) 36.1–37.1 (36.7)
Heart rate (bpm) 75–117 (92) 75–107 (88) 73–94 (83) 67–94 (80) 65–92 (82)
TABLE 3 Blood profile and biochemical test results
Parameter Range (median) Normal value
Day 1 Day 7
Peripheral blood test
Hemoglobin (g/L) 80.6–148 (118) 103–136 (113) 120–160
Red blood cell (9109/L) 3–4.91 (3.92) 3.47–4.94 (3.67) 4–5.5
White blood cell (9109/L) 6.71–30.1 (10.1) 8.77–15.6 (9.89) 4–10
Neutrophil count (9109/L) 4.99–27.4 (9.63) 6.61–14.8 (8.15) 2–7
Platelet count (9109/L) 95.4–356 (199) 105–336 (230) 100–300
Liver function tests
Aspartate aminotransferase (U/L) 14–99 (25) 14–43 (42) 0–46
Alanine aminotransferase (U/L) 10–116 (27) 13–65 (30) 0–46
TB (lmol/L) .19–1.76 (1.25) 8.4–18.4 (13.2) 0–25
DBILI (lmol/L) .2–12.5 (3.8) 1.8–6.2 (5.8) 0–7
IBILI (lmol/L) 2.9–17.9 (8.8) 5.5–12.56 (10.3) 1.5–18
TP (g/L) 41.3–71 (63.2) 54.1–72.3 (69.2) 60–80
ALB (g/L) 26.6–45.1 (24.2) 30.5–42.6 (40.2) 35–55
GLB (g/L) 14.6–30.4 (24.2) 18.5–29.7 (24.1) 20–30
Gamma glutamyl transferase (g/L) 8–84 (20) 19–135 (37) 5–55
Alkaline phosphatase (U/L) 41–99 (70) 65–146 (98) 35–134
Renal function tests
Blood urea nitrogen (mmol/L) 1.69–6.68 (3.27) 2.9–8.92 (4.08) 1.7–7.2
Creatine (lmol/L) 47.2–103.8 (59) 49.3–91.2 (70.2) 45–117
Electrolytes
K? (mmol/L) 3.68–4.9 (4.2) 3.08–6.52 (4.22) 3.5–5.5
Na? (mmol/L) 130–141.7 (136.1) 133.5–141 (137.4) 135–145
Cl- (mmol/L) 99–114.6 (103.7) 94.5–111.9 (102.9) 96–106
Ca2? (mmol/L) 1.81–2.9 (2.25) 2.18–2.4 (2.26) 2–2.7
TB total bilirubin, DBILI direct bilirubin, IBILI indirect bilirubin, TP total protein, ALB albumin, GLB globulin
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due to the long duration of the operations, leading to more
bleeding and hypoproteinemia, but the patients were suc-
cessfully treated with plasma and albumin transfusion and
diuretics. There was no intestinal perforation, no anasto-
mosis leakage, no bowel obstruction, and no intra-
abdominal hemorrhage or infections. These results indicate
that our combined approach is a relatively safe modality of
treatment with few postoperative complications.
To achieve effective cytoreduction, the field of surgery
should be wide, and multiple organ parts maybe resected.19
This leads to high risks of major postoperative complica-
tions with 14% to 55% morbidity rate and 0% to 19%
mortality rate, such as digestive fistulas and generalized
sepsis in particular.20 In a prospective study by Yan et al.
on 80 patients undergoing CRS ? HIPEC for nonappen-
diceal PC, 1 patient died (1.3%) on the postoperative day
22 from multiorgan failure, 11 patients (14%) developed 12
grade I adverse events, 40 patients (50%) developed 71
grade II adverse events, 36 patients (45%) experienced 49
grade III adverse events, and 6 patients (8%) experienced 8
grade IV adverse events.21 In our study, however, no
serious adverse events were observed, except for grade I
generalized edema in two patients (9.5%) who were suc-
cessfully treated. Such good results could be attributed to
the following: (1) a fixed team of well-experienced sur-
geons, nursing, and operating room staff; (2) relatively
mild HIPEC approach (hydroxycamptothecin, HCPT
20 mg plus MMC 30 mg for 60 min) compared with other
approach (MMC 120 mg/m2 ? cisplatin 200 mg/m2 for 90
to 120 min)20; (3) relaxation suture in closing abdominal
wound; (4) postoperative use of effective broad-spectrum
antibiotics to cover gram-positive and gram-negative aer-
obes and anaerobes; (5) transfusion of large-volume plasma
and coagulation factors to quickly restore hypoproteinemia
and stop bleeding; and (6) good nutritional support and
quick restoration of electrolyte balance.
The median follow-up for the 21 patients was
22.5 months. The 1-year survival rate among all the
patients was 66.7%. Among the 11 patients who died, the
CCR scores were 3 in seven patients, 2 in two patients, 1 in
one patient, and 0 in one patient, suggesting a close cor-
relation between CCR and survival. The CCR is the most
important prognostic indicator for survival.10,14,22,23 The
patients with optimal CRS followed by HIPEC showed the
best 5-year survival rate of 30%, whereas those underwent
incomplete CRS gained little benefit, with a median sur-
vival comparable to that reported in historical controls.24 In
a study by Cavaliere et al., patients with a CCR score of 0
had far higher 3-year survival rates than those with CCR
scores of 1 and 2 (the P \ .001).25 In 2004, Glehen et al.
published a large-scale multicentric prospective study
involving 506 patients who underwent CRS ? HIPEC
from 28 centers. The average follow-up was 53 months;
the mean survival time was 19.2 months; and the 1, 3, and
5-year survival rates were 72%, 39%, and 19%, respec-
tively. Thirty-eight patients survived for [5 years.26 In
2005, Netherland Cancer Research center summarized
phase I, II, and III clinical studies and analyzed the long-
term cure effects of 117 patients receiving CRS ? HIPEC.
The median survival time was 21.8 months, and the 1-, 3-,
and 5-year survival rates were 75%, 28%, and 9%,
respectively. Fifty-nine patients received complete cytore-
duction; median survival time was 42.9 months, and 1-, 3-,
and 5-year survival rates were 94%, 56%, and 43%,
respectively.22
Despite CRS, the disease recurrence rate is still high,
leading to treatment failure. In a multi-institutional study

















































All PC patients (n = 21)
PC of gastric cancer (n = 12)
PC of colorectal cancer (n = 5)
FIG. 1 Overall survival curve of 21
patients with disease of gastric,
colorectal, and ovarian origins
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73.3%.23 In a prospective study by Bijelic et al., among 70
patients with colorectal cancer undergoing combined
treatment, 49 developed documented recurrence at median
time for progression of 9 months, and most recurrent dis-
ease occurred inside the abdomen.24 One possible cause for
such a high failure rate could be the marked differences in
drug sensitivity between different PC types and between
individuals with the same tumor types, as was found in a
recent study of patient PC samples.27
In conclusion, CRS ? HIPEC is a relatively safe treat-
ment option in selected patients with PC that originates
from gastrointestinal tract and gynecological malignancies,
resulting in improved outcomes. There are still many
problems about CRS ? HIPEC, and a higher-level clinical






Sex Diagnosis PCI Operation (CRS ? HIPEC) CCRb Survival
status
1 72 F Krukenberg tumor 12 Uterus ovary, pelvic peritoneum, fossa iliaca peritoneum visceral
resection.
3 29.5 mo
2 45 F Rectal cancer 11 Rectum cancer resection, part pelvic peritoneum resection 1 18 mo
3 46 F Krukenberg tumor 5 Subtotal gastrectomy, ovariectomy, epigastric peritoneum visceral
resection
0 SWOT
4 50 M Gastric cancer 2 Subtotal gastrectomy, resection of part left upper quadrant of the abdomen
peritoneum
0 SWOT
5 30 M Gastric cancer 13 Total gastrectomy, splenectomy, partial pancreatectomy, resection of left
upper quadrant of the abdomen peritoneum
3 8 mo
6 70 M Gastric cancer 4 Subtotal gastrectomy, peritonectomy on the left upper quadrant 0 10.5 mo
7 37 F Colon cancer 26 Right semicolectomy, jejunum and mesenterium tumor resection, lower
abdominal and pelvic peritoneum resection
2 SWT
8 36 F Rectal cancer
recurrence in
ovary
14 Rectum cancer resection, adnexa uteri resection, pelvic peritoneum
resection, part bladder resection
3 8.5 mo
9 69 M Gastric cancer 2 Subtotal gastrectomy, peritonectomy on upper left quadrant 0 SWOT
10 54 F Gastric cancer 2 Gastric cancer resection, part upper quadrant of the abdomen peritoneum
resection
0 SWOT
11 36 M Colon cancer 6 Descending colon cancer resection, right lower quadrant of peritoneum
resection
0 SWOT
12 67 F Gastric cancer 6 Gastric cancer resection, left upper quadrant of the abdomen peritoneum
resection
0 15 mo
13 43 M Remnant gastric
cancer
18 Remnant gastric cancer resection, spleen and cauda pancreatic resection,
left upper quadrant of the abdomen peritoneum resection
3 9.5 mo
14 40 M Gastric cancer 9 Total gastrectomy, left upper quadrant of the abdomen peritoneum
resection
2 12 mo
15 38 F Colon cancer 13 Ascending colon resection, right quadrant of peritoneum, and pelvic
peritoneum resection
3 15.5 mo
16 69 M Gastric cancer 2 Subtotal gastrectomy, left upper quadrant peritonectomy 0 SWOT
17 41 F Gastric cancer 2 Subtotal gastrectomy, left upper quadrant peritonectomy 0 SWOT
18 59 F Ovarian cancer 8 Adnexectomy, colic omentum resection, iliac fossa and pelvic peritoneum
resection
1 SWT
19 67 F Ovary cancer 29 Ovariectomy, resection of pelvic peritoneum, colic omentum, and
diaphragmatic membrane
3 9 mo
20 64 F Malignant
peritoneum
mesothelioma
30 Transverse colon resection, partial small intestine resection, colic
omentum and epigastric peritoneum resection
3 30.5 mo
21 60 F Pseudomyxoma
peritonei
33 Hepatic region peritoneum, splenic region peritoneum, and pelvic
peritoneum resection
3 SWT
CCR completeness of cryoreduction, SWT survival with tumor, SWOT survival without tumor, PCI peritoneal carcinomatosis index
a Follow-up continued until August 1, 2008, either by outpatient clinic or by telephone
b A CCR score of 0 indicates no residual peritoneal disease after CRS; 1, \2.5 mm of residual disease; 2, residual tumor between 2.5 mm and
2.5 cm; and 3, [2.5 cm of residual tumor or the presence of a sheet of unresectable tumor nodules
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trial is needed to provide more supportive evidence and to
standardize the procedure.28–30 On the basis of these results,
we have registered and started a phase II randomized clin-
ical trial (NCT00454519; http://www.clinicaltrials.gov).
We hope that this trial will help gain better evidence to
support this procedure.
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